Current Board Term Ends 2024-07-31

Angela Dyer currently serves as Vice President, Regulatory Affairs with Emergent BioSolutions Canada Inc, having over 20  years of experience in the biotech industry. In her current role, Angela oversees the entire Emergent development product portfolio, from Phase 1 through licensure, including vaccines, therapeutics, and devices. Angela has overseen multiple NDS and BLA submissions focusing on medical countermeasures, emerging public health threats and pandemic preparedness.  Angela is skilled in novel and expedited regulatory pathways including Animal Rule, Extraordinary Use New Drug Submission, Fast Track, Orphan Drug and Priority Review. Angela has a Ph.D. in Molecular Virology from the University of British Columbia, and completed her post-doctoral research in Virology at the London School of Hygiene and Tropical Medicine. In her time serving on the CAPRA Board of Directors, Angela has enabled partnerships with provincial-level industry associations in order to bring CAPRA programming to all its members, no matter their geography. In addition to her work in biotech, Angela is a Certified Executive Coach and has an active leadership coaching practice.  A lifelong learner, Angela is keenly interested in the art of leadership and how to develop strong, high-performing teams. 

Current Board Term Ends 2024-07-31 

Mrs. Bouchard has 20 years of experience, including 15 years in global regulatory affairs. She has been involved in the preparation of numerous applications and submissions, including INDs/CTAs to regulatory agencies and ethics committees, marketing applications (such as NDAs/BLAs/NDSs/MAAs), as well as pediatric plans. She has also been involved in and supported many types of meetings with regulatory agencies, such as pre-IND/CTA, FDA Types B and C, Scientific Advice, pre-NDS/MAA, FDA Advisory Board. 

She has experience in various therapeutic indications, mainly endocrinology and metabolism, hematology, immunology, neurology, respiratory, women’s health and psychiatry. At PRA Health Sciences, she leads a team of forty regulatory affairs professionals located in North, Central and South America.

Prior to joining PRA in 2013, she acted as a Regulatory Project Manager in a pharmaceutical company for a few years, after evolving in various quality assurance and regulatory roles in a Montreal-based biotechnology for thirteen years. Mrs. Bouchard is a passionate leader, willing to share and learn from each other's experience and expertise. She would be grateful to have the opportunity to serve CAPRA and support its growth, as the regulatory affairs field expands and evolves.

Current Board Term Ends 2025-07-31 

Danny has over 20 years of experience in developing regulatory strategies, leading registration and supporting launches of pharmaceuticals and biologics in Canada and international markets at Cato Research, Shire, Avir Pharma / Laboratoire Riva and JAMP Pharma, where he is currently heading the regulatory, pharmacovigilance and medical information teams. Danny is also responsible for the Regulatory Affairs option of the Masters Program in Drug Development at Université de Montréal. Serving on the CAPRA Board of Directors for the past 3 years (as Corporate Secretary and now Treasurer), Danny volunteers on the CAPRA Symposium Committee since 2003 and has been contributing author for the RAPS Fundamentals of Canadian Regulatory Affairs, Danny holds an M.Sc. in Drug Development (Regulatory Affairs), an MBA and is RAC-certified.

Current Board Term Ends 2024-07-31

Sandra Ireland is an accomplished and highly driven Regulatory Affairs and Quality Assurance executive with over 25 years of experience providing regulatory affairs, clinical affairs and quality strategies for small, medium and large domestic and international healthcare companies. She is a regulatory affairs certified (RAC) professional specializing in pharmaceutical drugs, medical devices, natural health products and cosmetics.

Sandra is the President of RaQa Consulting Inc. and Regulatory Solutions Inc. She is a part-time professor at Seneca College in the Pharmaceutical Regulatory Affairs and Quality Operations, as well as Cosmetic Science programs. Sandra is also involved with the Applied Research & Innovation projects at Seneca College.

She has been a member of CAPRA since 2001. Sandra received her B.Sc. in Biochemistry and Chemistry from the University of Western Ontario. She also holds a post-degree certification in Pharmaceutical Regulatory Affairs & Quality Operations from Seneca College, a Clinical Research Associate Diploma from the Michener Institute in Toronto, and an executive MBA from Athabasca University.

Current Board Term Ends 2025-07-31 

Bhavesh has 14 years of experience in Regulatory Affairs in Canada. His regulatory experience encompasses pharmaceutical drugs, natural health products, medical devices, cosmetics, and foods. Currently, he is the Board Lead at Education Day committee and working at Apotex Inc. Bhavesh has honor to wrote two chapters for the RAPS 2018 book, “Fundamentals of Canadian Pharmaceutical and Biologics Regulations”. He feels honored to co-design the Natural Health Product course at Seneca College, Toronto.

Current Board Term Ends 2025-07-31

Krista Coventry is the Senior Director of Clinical Affairs & Regulatory Strategy for Source Nutraceutical, Inc., a Canadian contract research organization. She is a regulatory affairs specialist with over 20 years of experience providing project management, regulatory strategies and market compliance solutions to industry clients, globally. Krista has expert knowledge of acts, regulations, policies and guidelines relating to natural health products, over-the-counter drugs, foods, cosmetics and medical devices; as well as clinical research requirements in these same fields. She has worked extensively with Canadian and U.S. regulatory frameworks to advise industry clients on various pre-market requirements (claims, labelling, safety prerequisites, clinical trials) in support of regulatory compliance initiatives in North American markets. She also specializes in strategic planning for health product commercialization, and has broad expertise in the critical evaluation of evidence-based clinical research in support of regulatory portfolios. Krista has held numerous distinguished volunteer affiliations with regulatory-based professional societies in North America and is a longstanding CAPRA volunteer. She has given 10 years of service to the CAPRA Board of Directors (2012-2023) and is the current Board Lead for Marketing.

Current Board Term Ends 2025-07-31

Queenia holds the position of Associate Director of Global Regulatory Intelligence & Policy at Apotex. She utilizes her years of pharmaceutical experience in Regulatory Operations, Regulatory Affairs, CMC & QA to support the CAPRA organization. As the Chair of the CAPRA Symposium Committee, she collaborates with Health Canada and industry colleagues regularly. She has led a dedicated symposium team to regularly offer CAPRA members numerous regulatory workshops to keep members up to date for over 15 years. She would like to thank all CAPRA members for their continued support.

Current Board Term Ends 2024-07-31 

Dr. Sherry Boodram is the CEO and Co-Founder of CannDelta Inc., a leading cannabis and psychedelics regulatory consulting company. She also serves as an Independent Board Advisor for a publicly traded Canadian cannabis extraction technology company. She has been a guest lecturer at local institutions including Osgoode Hall Law School, Seneca College, Humber College and the North American College of Pharmaceutical Technology to teach about domestic and international cannabis regulations.

Prior to founding CannDelta Inc., she spent several years at Health Canada as a Senior Regulatory Compliance Officer/Auditor where she was responsible for cannabis licensing application reviews and facility inspections under various cannabis regimes. She holds a Ph.D. in Chemistry from York University, a Hon. B.Sc. in Biological Chemistry from the University of Toronto, a Certificate in Cannabis Law and Regulation from Osgoode Hall Law School of York University, and a Graduate Certificate with Honours in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College.

Sherry specializes in cannabis and psychedelics licensing submissions, international policy and regulation development, strategic mergers and acquisitions, due diligence inspections and audits, internal quality management systems, facility design, operational optimization, product registrations, and education. As the Chair of the CAPRA Webinar Committee, she aims to expand the knowledge base and existing regulatory network of the CAPRA community to build stronger relationships and provide increased professional and academic support.

Current Board Term Ends 2024-07-31

Sorin Alb received his Honours Certificate in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College in 2008, earned the RAC (CAN) designation in 2009 and again in 2017, and is currently working as a Senior Manager Regulatory Affairs for PPD Canada, part of Thermo Fisher Scientific. His professional interests focus on Canadian pharmaceuticals, small chemical molecules and biologics, supporting both new drugs’ applications as well as Post Licencing Management RA activities.  Sorin provides technical/project leadership over several regions or globally, providing innovative solutions including regulatory expertise and client interface to provide strategic regulatory intelligence, and guidance supporting product development from preclinical through registration and product optimization. Provides strategic, expedient and efficient preparation of client deliverables that meet current local, regional and ICH regulatory and technical requirements. Acts as key liaison with internal and external clients in the provision and marketing of these services. In his second year on the CAPRA Board of Directors, Sorin now leads the NOC editorial board, while continuing his interest in eCTD submissions, Regulatory Enrolment Process and effective online communication for the betterment of all Regulatory professionals.

Current Board Term Ends 2025-07-31

Audra has over 18 years of regulatory experience in the pharmaceutical industry. Her experience in regulatory affairs includes a broad range of activities with both small and large sized pharmaceutical companies, and includes activities from clinical development through marketed product/post-marketing activities. She has prepared scientific and regulatory documents for inclusion within Health Canada submissions, managing a number of New Drug Submissions through to approval. Her regulatory role has provided her the opportunity to interface directly with Health Canada for both pre-CTA and pre-NDS meetings.  In recent years, Audra has focused her career on supporting small to midsize companies through their clinical development programs.

 She obtained her BSc. in Biology from the University of Toronto and a Graduate Certificate in Regulatory Affairs from the Humber Institute of Technology and Advanced Learning.

Current Board Term Ends 2025-07-31

 Danielle Mason is a Senior Manager, Regulatory Affairs at TPIreg, Innomar Strategies Inc.  Danielle has been in the pharmaceutical industry for more than 20 years and has broad experience across various dosage types and specialties (solids, liquids, parenterals and biologics).   Danielle provides regulatory consulting support for both prescription drugs and medical devices.  In a secondary role as a Quality-Regulatory-Safety (QRS) Program Manager that includes several marketed products, Danielle serves as key Client liaison to ensure cross-functional activities are aligned and product activities comply with regulatory requirements.

 As part of her consulting role, Danielle has provided training to colleagues for new regulatory initiatives.  She has also provided project management training to recent graduates and working professionals who are seeking roles in regulatory affairs and the healthcare industry.  This experience sparked Danielle’s interest to lead the Student Relations Committee within CAPRA as she enjoys sharing her knowledge and experience to help others. Danielle graduated from University of Guelph in 2000 with a degree in Biological Engineering and earned the Project Management Professional certification in 2013.

Current Board Term Ends 2025-07-31

Samar began her career in basic research in private and hospital settings, before transitioning to Regulatory Affairs. Currently, Samar is the Director of Regulatory Affairs at Boehringer-Ingelheim (Canada) Ltd., a global family owned Pharmaceutical Company. Samar’s proficiency includes over 29 years of experience in progressive roles in the Pharmaceutical Industry, with more than 22 years of proven strategic leadership and people management skills, motivating various teams in different functions to deliver high quality results in line with business priorities.

She graduated from the University of Western Ontario with a Master of Science degree in Molecular Biology, and most recently completed her Executive Master of Business Administration degree from the Ivey Business School in London, Ontario, Canada.

Current Board Term Ends 2025-07-31

Mỹ has 20 years of drugs and some biologics regulatory affairs experience in the global pharmaceutical industry across various therapeutic areas.   Mỹ has also held various positions in quality assurance, spearheading inspections with Health Canada and CFIA (Canadian Food Inspection Agency) and in pharmacovigilance, and medical information bringing a broad perspective to her work in regulatory affairs.  In RA, she has experience in performing due diligence evaluations/submission gap analyses, establishing regulatory strategies, and overseeing various types of regulatory submissions including NDSs, SNDSs, CTAs, generic submissions and submissions for animal health products with the VDD and CFIA, etc.  Mỹ is skilled at providing technical guidance and expertise in the management of regulatory projects to optimize opportunities for successful outcomes.  Currently, she serves on the Board of Directors for CAPRA and is actively involved in DIA Canada’s Program Committee.  Outside of work, she a passionate leader mentoring/coaching students at McMaster University and serves on the Board of Directors for Canadian Parents for French, promoting bilingualism in Ontario for the next generation.  Mỹ obtained her M.B.A and B.Sc., from McMaster University.  

Current Board Term Ends 2024-07-31

Angela Dyer currently serves as Vice President, Regulatory Affairs with Emergent BioSolutions Canada Inc, having over 20  years of experience in the biotech industry. In her current role, Angela oversees the entire Emergent development product portfolio, from Phase 1 through licensure, including vaccines, therapeutics, and devices. Angela has overseen multiple NDS and BLA submissions focusing on medical countermeasures, emerging public health threats and pandemic preparedness.  Angela is skilled in novel and expedited regulatory pathways including Animal Rule, Extraordinary Use New Drug Submission, Fast Track, Orphan Drug and Priority Review. Angela has a Ph.D. in Molecular Virology from the University of British Columbia, and completed her post-doctoral research in Virology at the London School of Hygiene and Tropical Medicine. In her time serving on the CAPRA Board of Directors, Angela has enabled partnerships with provincial-level industry associations in order to bring CAPRA programming to all its members, no matter their geography. In addition to her work in biotech, Angela is a Certified Executive Coach and has an active leadership coaching practice.  A lifelong learner, Angela is keenly interested in the art of leadership and how to develop strong, high-performing teams. 

Current Board Term Ends 2025-07-31 

Danny has over 20 years of experience in developing regulatory strategies, leading registration and supporting launches of pharmaceuticals and biologics in Canada and international markets at Cato Research, Shire, Avir Pharma / Laboratoire Riva and JAMP Pharma, where he is currently heading the regulatory, pharmacovigilance and medical information teams. Danny is also responsible for the Regulatory Affairs option of the Masters Program in Drug Development at Université de Montréal. Serving on the CAPRA Board of Directors for the past 3 years (as Corporate Secretary and now Treasurer), Danny volunteers on the CAPRA Symposium Committee since 2003 and has been contributing author for the RAPS Fundamentals of Canadian Regulatory Affairs, Danny holds an M.Sc. in Drug Development (Regulatory Affairs), an MBA and is RAC-certified.

Current Board Term Ends 2025-07-31

Krista Coventry is the Senior Director of Clinical Affairs & Regulatory Strategy for Source Nutraceutical, Inc., a Canadian contract research organization. She is a regulatory affairs specialist with over 20 years of experience providing project management, regulatory strategies and market compliance solutions to industry clients, globally. Krista has expert knowledge of acts, regulations, policies and guidelines relating to natural health products, over-the-counter drugs, foods, cosmetics and medical devices; as well as clinical research requirements in these same fields. She has worked extensively with Canadian and U.S. regulatory frameworks to advise industry clients on various pre-market requirements (claims, labelling, safety prerequisites, clinical trials) in support of regulatory compliance initiatives in North American markets. She also specializes in strategic planning for health product commercialization, and has broad expertise in the critical evaluation of evidence-based clinical research in support of regulatory portfolios. Krista has held numerous distinguished volunteer affiliations with regulatory-based professional societies in North America and is a longstanding CAPRA volunteer. She has given 10 years of service to the CAPRA Board of Directors (2012-2023) and is the current Board Lead for Marketing.

Current Board Term Ends 2025-07-31

Queenia holds the position of Associate Director of Global Regulatory Intelligence & Policy at Apotex. She utilizes her years of pharmaceutical experience in Regulatory Operations, Regulatory Affairs, CMC & QA to support the CAPRA organization. As the Chair of the CAPRA Symposium Committee, she collaborates with Health Canada and industry colleagues regularly. She has led a dedicated symposium team to regularly offer CAPRA members numerous regulatory workshops to keep members up to date for over 15 years. She would like to thank all CAPRA members for their continued support.

Current Board Term Ends 2024-07-31

Sorin Alb received his Honours Certificate in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College in 2008, earned the RAC (CAN) designation in 2009 and again in 2017, and is currently working as a Senior Manager Regulatory Affairs for PPD Canada, part of Thermo Fisher Scientific. His professional interests focus on Canadian pharmaceuticals, small chemical molecules and biologics, supporting both new drugs’ applications as well as Post Licencing Management RA activities.  Sorin provides technical/project leadership over several regions or globally, providing innovative solutions including regulatory expertise and client interface to provide strategic regulatory intelligence, and guidance supporting product development from preclinical through registration and product optimization. Provides strategic, expedient and efficient preparation of client deliverables that meet current local, regional and ICH regulatory and technical requirements. Acts as key liaison with internal and external clients in the provision and marketing of these services. In his second year on the CAPRA Board of Directors, Sorin now leads the NOC editorial board, while continuing his interest in eCTD submissions, Regulatory Enrolment Process and effective online communication for the betterment of all Regulatory professionals.

Current Board Term Ends 2025-07-31

Audra has over 18 years of regulatory experience in the pharmaceutical industry. Her experience in regulatory affairs includes a broad range of activities with both small and large sized pharmaceutical companies, and includes activities from clinical development through marketed product/post-marketing activities. She has prepared scientific and regulatory documents for inclusion within Health Canada submissions, managing a number of New Drug Submissions through to approval. Her regulatory role has provided her the opportunity to interface directly with Health Canada for both pre-CTA and pre-NDS meetings.  In recent years, Audra has focused her career on supporting small to midsize companies through their clinical development programs.

 She obtained her BSc. in Biology from the University of Toronto and a Graduate Certificate in Regulatory Affairs from the Humber Institute of Technology and Advanced Learning.

Current Board Term Ends 2025-07-31

 Danielle Mason is a Senior Manager, Regulatory Affairs at TPIreg, Innomar Strategies Inc.  Danielle has been in the pharmaceutical industry for more than 20 years and has broad experience across various dosage types and specialties (solids, liquids, parenterals and biologics).   Danielle provides regulatory consulting support for both prescription drugs and medical devices.  In a secondary role as a Quality-Regulatory-Safety (QRS) Program Manager that includes several marketed products, Danielle serves as key Client liaison to ensure cross-functional activities are aligned and product activities comply with regulatory requirements.

 As part of her consulting role, Danielle has provided training to colleagues for new regulatory initiatives.  She has also provided project management training to recent graduates and working professionals who are seeking roles in regulatory affairs and the healthcare industry.  This experience sparked Danielle’s interest to lead the Student Relations Committee within CAPRA as she enjoys sharing her knowledge and experience to help others. Danielle graduated from University of Guelph in 2000 with a degree in Biological Engineering and earned the Project Management Professional certification in 2013.

Current Board Term Ends 2025-07-31

Samar began her career in basic research in private and hospital settings, before transitioning to Regulatory Affairs. Currently, Samar is the Director of Regulatory Affairs at Boehringer-Ingelheim (Canada) Ltd., a global family owned Pharmaceutical Company. Samar’s proficiency includes over 29 years of experience in progressive roles in the Pharmaceutical Industry, with more than 22 years of proven strategic leadership and people management skills, motivating various teams in different functions to deliver high quality results in line with business priorities.

She graduated from the University of Western Ontario with a Master of Science degree in Molecular Biology, and most recently completed her Executive Master of Business Administration degree from the Ivey Business School in London, Ontario, Canada.